Dexamethasone in the treatment of meningeal leukemia.
To determine if dexamethasone has a role in the treatment of meningeal leukemia, 8 consecutive patients with acute lymphoblastic and signs or symptoms of CNS were included in the study. After the confirmation of leukemic blast cells on cerebrospinal fluid, they received intrathecal and IV dexamethasone; 3 days later the patients received "triple" intrathecal chemotherapy with dexamethasone, methotrexate and cytarabine, and the spinal fluid was studied again. All patients had good clinical response and 7 out of the 8 patients showed reduction on the CSF cell count after the use of dexamethasone alone. The results suggest that dexamethasone is a lymphocytic agent that could play a more active role in the prevention and therapy of meningeal leukemia and should be preferred over hydrocortisone in the so called "triple" intrathecal chemotherapy for the prevention and treatment of CNS leukemia.
Gómez-Almaguer
D
D
Department of Hematology, Hospital Universitairo UANL, Monterrey, Mexico.
González-Llano
O
O
Montemayor
J
J
Jaime-Pérez
J C
JC
Galindo
C
C
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002452:Cell Count; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged
D003561:Cytarabine; D003907:Dexamethasone; D008727:Methotrexate